Top Biotechnology Startups in 2027

Amia.ai develops AI systems purpose-built for the life sciences to accelerate regulatory science and reduce operational burden. Its flagship product, MedNova, is an AI copilot for regulatory submission workflows that automates complex documentation like eCTD Modules 3 and 5, enabling teams to prepare FDA- and EMA-ready submissions up to 10x faster. Powered by BioPharmLLM, Amia’s proprietary language model trained on scientific and regulatory data, MedNova delivers safe, auditable outputs designed for GxP environments. Founded by industry veterans from Pfizer, Amgen, and Gilead, Amia.ai serves biotech startups, regulatory consultancies, and enterprise pharma teams seeking next-generation AI tooling built for compliance and accuracy.

Claryx is building the hospital immune system, reading the genomes of confirmed patient infections, linking related cases as outbreaks, and tracing each back to its likely source. When that source is in the building (a sink, a shared piece of equipment, a particular room), Claryx finds it by matching the patient's strain against a digital twin of the hospital's microbiome, sequenced from its air, its water and its surfaces, all on proprietary chemistry cheap enough to run continuously. Founded by brothers Kurt and Dirk Hackenberger, Claryx is based in New York and live across multiple health systems.

While consumer wearables report what happened yesterday, we are building a closed-loop biometric platform that equips professional recovery, physical therapy, and longevity practitioners with actionable guidance today. By pairing purpose-built white-label hardware with real-time autonomic nervous system monitoring via the Pelican Kit, our system integrates seamlessly with elite diagnostic tools like DEXA scanners. We operate an 80% asset-light international licensing model—partnering with regional operators to handle physical execution and local CapEx while we provide the pure-play SaaS and telemetry architecture